Literature DB >> 389996

Studies of immunoreactivity to human lacrimal gland fractions in patients with ophthalmic Graves' disease.

J R Wall, A Trewin, S L Fang, S H Ingbar, L E Braverman.   

Abstract

In vitro evidence for immunoreactivity against human lacrimal gland fractions was sought in patients with ophthalmic Graves' disease. There was no significant increase in interstitial lymphoid tissue on lacrimal gland biopsy. Serum antibodies against lacrimal fractions were not detected using the indirect immunofluorescent technique. Using the tanned cell hemagglutination test with lacrimal antigen, antibodies were detected in 2 of 15 patients with eye disease, 2 of 15 hyperthyroid patients without eye disease, and 2 of 20 normal subjects. Macrophage inhibitory factor (MIF) production in response to human lacrimal extract was not demonstrated in any of 11 patients with eye disease tested. On the other hand, MIF was demonstrated in 2 of 10 patients with Graves' disease selected for absence of eye disease. Significant peripheral blood lymphocyte transformation in response to human lacrimal extract, or a soluble or membrane fraction, was demonstrated in 9 of 22 patients tested; in 6 of 21 patients to extract, in 3 of 21 patients to a soluble fraction and in 7 of 10 patients to a membrane fraction. The possible significance of lacrimal gland inflammation and role(s) in the pathogenesis of ophthalmic Graves' disease are discussed.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 389996     DOI: 10.1007/BF03350389

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  40 in total

1.  PARALLEL ASSAYS OF THYROTROPHIN, LONG-ACTING THYROID STIMULATOR AND EXOPHTHALMOS-PRODUCING SUBSTANCE IN ENDOCRINE EXOPHTHALMOS AND PRETIBIAL MYXEDEMA.

Authors:  B L PIMSTONE; R HOFFENBERG; E BLACK
Journal:  J Clin Endocrinol Metab       Date:  1964-10       Impact factor: 5.958

2.  Relationships between the submaxillary gland and the thymus.

Authors:  A Martinez-Hernandezo; P K Nakane; G B Pierce
Journal:  Lab Invest       Date:  1973-08       Impact factor: 5.662

3.  Thyroid-stimulating immunoglobulins in Graves' disease.

Authors:  B R Smith; R Hall
Journal:  Lancet       Date:  1974-08-24       Impact factor: 79.321

4.  Binding of thyroglobulin and thyroglobulin-antithyroglobulin immune complex to extraocular muscle membrane.

Authors:  J Konishi; M M Herman; J P Kriss
Journal:  Endocrinology       Date:  1974-08       Impact factor: 4.736

5.  Delayed hypersensitivity in Graves' disease and exophthalmos: identification of thyroglobulin in normal human orbital muscle.

Authors:  B R Mullin; R E Levinson; A Friedman; D E Henson; R J Winand; L D Kohn
Journal:  Endocrinology       Date:  1977-02       Impact factor: 4.736

6.  The spectrum of benign to malignant lymphoproliferation in Sjögren's syndrome.

Authors:  L G Anderson; N Talal
Journal:  Clin Exp Immunol       Date:  1972-02       Impact factor: 4.330

7.  Impaired Lymphocyte Transformation and Delayed Hypersensitivity in Sjögren's Syndrome.

Authors:  B G Leventhal; D S Waldorf; N Talal
Journal:  J Clin Invest       Date:  1967-08       Impact factor: 14.808

8.  Antibodies to salivary duct cells, and other autoantibodies, in patients with Sjögren's syndrome and other idiopathic autoimmune diseases.

Authors:  T E Feltkamp; A L van Rossum
Journal:  Clin Exp Immunol       Date:  1968-01       Impact factor: 4.330

9.  Cell-mediated immunity in the exophthalmos of Graves' disease as demonstrated by the migration inhibition factor (MIF) test.

Authors:  R E Munro; L Lamki; V V Row; R Volpé
Journal:  J Clin Endocrinol Metab       Date:  1973-08       Impact factor: 5.958

10.  Localization of antigen in tissue cells; improvements in a method for the detection of antigen by means of fluorescent antibody.

Authors:  A H COONS; M H KAPLAN
Journal:  J Exp Med       Date:  1950-01-01       Impact factor: 14.307

View more
  8 in total

Review 1.  Autoimmunity in Graves' ophthalmopathy: a review.

Authors:  A P Weetman
Journal:  J R Soc Med       Date:  1989-03       Impact factor: 5.344

2.  T and B cell reactivity to extraocular and skeletal muscle in Graves' ophthalmopathy.

Authors:  A P Weetman; P Fells; B Shine
Journal:  Br J Ophthalmol       Date:  1989-05       Impact factor: 4.638

Review 3.  Ocular manifestations of Graves' disease: a review.

Authors:  A P Weetman; A M McGregor; R Hall
Journal:  J R Soc Med       Date:  1984-11       Impact factor: 5.344

4.  Production of migration inhibitory factor in response to bacterial and fungal antigens in patients with untreated Graves' disease.

Authors:  J R Wall; E A Ryan
Journal:  Can Med Assoc J       Date:  1980-06-07       Impact factor: 8.262

5.  Antibodies against striated muscle, connective tissue and nuclear antigens in patients with thyroid-associated ophthalmopathy: should Graves' disease be considered a collagen disorder?

Authors:  J I Kiljanski; K Peele; I Stachura; J Pickeral; C Stolarski; J S Kennerdell; J R Wall
Journal:  J Endocrinol Invest       Date:  1997-11       Impact factor: 4.256

6.  Clinical significance of a new autoantibody against a human eye muscle soluble antigen, detected by immunofluorescence.

Authors:  M Mengistu; E Laryea; A Miller; J R Wall
Journal:  Clin Exp Immunol       Date:  1986-07       Impact factor: 4.330

7.  Luekocyte adherence inhibition in response to human orbital and lacrimal extracts in patients with Graves' ophthalmopathy.

Authors:  J R Wall; B A Walters; C Grant
Journal:  J Endocrinol Invest       Date:  1979 Oct-Dec       Impact factor: 4.256

Review 8.  Graves' ophthalmopathy.

Authors:  J R Wall; J Henderson; C R Strakosch; D M Joyner
Journal:  Can Med Assoc J       Date:  1981-04-01       Impact factor: 8.262

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.